nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—CYP1A2—Anagrelide—hematologic cancer	0.0403	0.0847	CbGbCtD
Asenapine—CYP2D6—Lomustine—hematologic cancer	0.0214	0.045	CbGbCtD
Asenapine—CYP1A2—Carmustine—hematologic cancer	0.0212	0.0445	CbGbCtD
Asenapine—CYP2D6—Idarubicin—hematologic cancer	0.0191	0.0401	CbGbCtD
Asenapine—CYP1A2—Methoxsalen—hematologic cancer	0.018	0.0379	CbGbCtD
Asenapine—CYP1A2—Bortezomib—hematologic cancer	0.0171	0.036	CbGbCtD
Asenapine—CYP1A2—Daunorubicin—hematologic cancer	0.0164	0.0344	CbGbCtD
Asenapine—CYP2D6—Hydroxyurea—hematologic cancer	0.0162	0.0341	CbGbCtD
Asenapine—CYP1A2—Alitretinoin—hematologic cancer	0.016	0.0337	CbGbCtD
Asenapine—CYP1A2—Thalidomide—hematologic cancer	0.0149	0.0314	CbGbCtD
Asenapine—CYP3A4—Bexarotene—hematologic cancer	0.0146	0.0308	CbGbCtD
Asenapine—CYP2D6—Bortezomib—hematologic cancer	0.0141	0.0297	CbGbCtD
Asenapine—CYP3A4—Lomustine—hematologic cancer	0.0136	0.0286	CbGbCtD
Asenapine—CYP3A4—Busulfan—hematologic cancer	0.0136	0.0286	CbGbCtD
Asenapine—CYP1A2—Dacarbazine—hematologic cancer	0.0128	0.027	CbGbCtD
Asenapine—CYP1A2—Imatinib—hematologic cancer	0.0125	0.0264	CbGbCtD
Asenapine—CYP3A4—Thiotepa—hematologic cancer	0.0121	0.0255	CbGbCtD
Asenapine—CYP2D6—Imatinib—hematologic cancer	0.0103	0.0217	CbGbCtD
Asenapine—CYP1A2—Dasatinib—hematologic cancer	0.0101	0.0212	CbGbCtD
Asenapine—CYP3A4—Methoxsalen—hematologic cancer	0.00943	0.0198	CbGbCtD
Asenapine—CYP2D6—Nilotinib—hematologic cancer	0.00939	0.0198	CbGbCtD
Asenapine—CYP2D6—Vinorelbine—hematologic cancer	0.00931	0.0196	CbGbCtD
Asenapine—CYP3A4—Bortezomib—hematologic cancer	0.00897	0.0189	CbGbCtD
Asenapine—CYP3A4—Daunorubicin—hematologic cancer	0.00858	0.018	CbGbCtD
Asenapine—CYP3A4—Cytarabine—hematologic cancer	0.00757	0.0159	CbGbCtD
Asenapine—CYP3A4—Teniposide—hematologic cancer	0.00745	0.0157	CbGbCtD
Asenapine—CYP3A4—Ifosfamide—hematologic cancer	0.00688	0.0145	CbGbCtD
Asenapine—CYP3A4—Imatinib—hematologic cancer	0.00657	0.0138	CbGbCtD
Asenapine—CYP1A2—Etoposide—hematologic cancer	0.00627	0.0132	CbGbCtD
Asenapine—CYP3A4—Ruxolitinib—hematologic cancer	0.00619	0.013	CbGbCtD
Asenapine—CYP3A4—Nilotinib—hematologic cancer	0.00597	0.0126	CbGbCtD
Asenapine—CYP3A4—Vinorelbine—hematologic cancer	0.00592	0.0125	CbGbCtD
Asenapine—CYP2D6—Vinblastine—hematologic cancer	0.00574	0.0121	CbGbCtD
Asenapine—CYP3A4—Triamcinolone—hematologic cancer	0.00541	0.0114	CbGbCtD
Asenapine—CYP3A4—Dasatinib—hematologic cancer	0.00528	0.0111	CbGbCtD
Asenapine—CYP3A4—Mitoxantrone—hematologic cancer	0.00521	0.011	CbGbCtD
Asenapine—CYP3A4—Betamethasone—hematologic cancer	0.00465	0.00977	CbGbCtD
Asenapine—CYP3A4—Prednisolone—hematologic cancer	0.00458	0.00964	CbGbCtD
Asenapine—CYP3A4—Prednisone—hematologic cancer	0.00433	0.00911	CbGbCtD
Asenapine—CYP2D6—Dexamethasone—hematologic cancer	0.00425	0.00894	CbGbCtD
Asenapine—CYP3A4—Irinotecan—hematologic cancer	0.0041	0.00863	CbGbCtD
Asenapine—CYP3A4—Vinblastine—hematologic cancer	0.00365	0.00767	CbGbCtD
Asenapine—CYP3A4—Vincristine—hematologic cancer	0.00359	0.00755	CbGbCtD
Asenapine—CYP2D6—Doxorubicin—hematologic cancer	0.00353	0.00742	CbGbCtD
Asenapine—CYP3A4—Etoposide—hematologic cancer	0.00329	0.00691	CbGbCtD
Asenapine—UGT1A4—hematopoietic system—hematologic cancer	0.00278	0.0832	CbGeAlD
Asenapine—CYP3A4—Dexamethasone—hematologic cancer	0.0027	0.00568	CbGbCtD
Asenapine—CYP3A4—Doxorubicin—hematologic cancer	0.00224	0.00472	CbGbCtD
Asenapine—UGT1A4—blood—hematologic cancer	0.00184	0.0551	CbGeAlD
Asenapine—HRH2—hematopoietic system—hematologic cancer	0.00174	0.0522	CbGeAlD
Asenapine—DRD4—testis—hematologic cancer	0.00154	0.0462	CbGeAlD
Asenapine—HRH2—blood—hematologic cancer	0.00115	0.0346	CbGeAlD
Asenapine—SLC6A4—hematopoietic system—hematologic cancer	0.00104	0.0313	CbGeAlD
Asenapine—HRH2—lung—hematologic cancer	0.00101	0.0303	CbGeAlD
Asenapine—HTR1A—hematopoietic system—hematologic cancer	0.000927	0.0278	CbGeAlD
Asenapine—HTR7—hematopoietic system—hematologic cancer	0.000886	0.0265	CbGeAlD
Asenapine—ADRA1A—hematopoietic system—hematologic cancer	0.000855	0.0256	CbGeAlD
Asenapine—CYP1A2—hematopoietic system—hematologic cancer	0.000707	0.0212	CbGeAlD
Asenapine—HRH2—lymph node—hematologic cancer	0.000692	0.0207	CbGeAlD
Asenapine—SLC6A4—blood—hematologic cancer	0.000692	0.0207	CbGeAlD
Asenapine—HTR2B—blood—hematologic cancer	0.000685	0.0205	CbGeAlD
Asenapine—HTR7—gonad—hematologic cancer	0.000674	0.0202	CbGeAlD
Asenapine—HRH1—hematopoietic system—hematologic cancer	0.000662	0.0198	CbGeAlD
Asenapine—ADRA2A—hematopoietic system—hematologic cancer	0.00065	0.0195	CbGeAlD
Asenapine—ADRB1—lung—hematologic cancer	0.000628	0.0188	CbGeAlD
Asenapine—SLC6A4—lung—hematologic cancer	0.000606	0.0182	CbGeAlD
Asenapine—HTR2B—lung—hematologic cancer	0.000601	0.018	CbGeAlD
Asenapine—HTR7—blood—hematologic cancer	0.000587	0.0176	CbGeAlD
Asenapine—ADRA1A—blood—hematologic cancer	0.000566	0.017	CbGeAlD
Asenapine—HTR2A—hematopoietic system—hematologic cancer	0.000552	0.0165	CbGeAlD
Asenapine—ADRA2C—blood—hematologic cancer	0.00054	0.0162	CbGeAlD
Asenapine—HTR7—lung—hematologic cancer	0.000515	0.0154	CbGeAlD
Asenapine—CYP3A4—hematopoietic system—hematologic cancer	0.000511	0.0153	CbGeAlD
Asenapine—CYP2D6—hematopoietic system—hematologic cancer	0.000503	0.0151	CbGeAlD
Asenapine—ADRA2A—gonad—hematologic cancer	0.000494	0.0148	CbGeAlD
Asenapine—DRD2—lung—hematologic cancer	0.000487	0.0146	CbGeAlD
Asenapine—HTR7—testis—hematologic cancer	0.000486	0.0145	CbGeAlD
Asenapine—ADRA2C—lung—hematologic cancer	0.000473	0.0142	CbGeAlD
Asenapine—CYP1A2—blood—hematologic cancer	0.000468	0.014	CbGeAlD
Asenapine—DRD2—testis—hematologic cancer	0.000459	0.0137	CbGeAlD
Asenapine—ADRA2C—testis—hematologic cancer	0.000446	0.0134	CbGeAlD
Asenapine—ADRA2A—blood—hematologic cancer	0.00043	0.0129	CbGeAlD
Asenapine—HTR2A—gonad—hematologic cancer	0.00042	0.0126	CbGeAlD
Asenapine—HTR2B—lymph node—hematologic cancer	0.000411	0.0123	CbGeAlD
Asenapine—CYP1A2—lung—hematologic cancer	0.00041	0.0123	CbGeAlD
Asenapine—HRH1—lung—hematologic cancer	0.000384	0.0115	CbGeAlD
Asenapine—ADRA2A—lung—hematologic cancer	0.000377	0.0113	CbGeAlD
Asenapine—HTR2A—blood—hematologic cancer	0.000366	0.011	CbGeAlD
Asenapine—HRH1—testis—hematologic cancer	0.000363	0.0109	CbGeAlD
Asenapine—ADRA2A—testis—hematologic cancer	0.000356	0.0107	CbGeAlD
Asenapine—CYP3A4—blood—hematologic cancer	0.000339	0.0101	CbGeAlD
Asenapine—CYP2D6—blood—hematologic cancer	0.000333	0.00998	CbGeAlD
Asenapine—ADRA2C—lymph node—hematologic cancer	0.000323	0.00969	CbGeAlD
Asenapine—HTR2A—lung—hematologic cancer	0.000321	0.00961	CbGeAlD
Asenapine—HTR2A—testis—hematologic cancer	0.000303	0.00907	CbGeAlD
Asenapine—CYP2D6—testis—hematologic cancer	0.000276	0.00826	CbGeAlD
Asenapine—HRH1—lymph node—hematologic cancer	0.000263	0.00787	CbGeAlD
Asenapine—ADRA2A—lymph node—hematologic cancer	0.000258	0.00773	CbGeAlD
Asenapine—Rash—Carmustine—hematologic cancer	6e-05	0.000188	CcSEcCtD
Asenapine—Dermatitis—Carmustine—hematologic cancer	5.99e-05	0.000188	CcSEcCtD
Asenapine—Vomiting—Alitretinoin—hematologic cancer	5.99e-05	0.000188	CcSEcCtD
Asenapine—Anaemia—Prednisone—hematologic cancer	5.97e-05	0.000187	CcSEcCtD
Asenapine—Headache—Carmustine—hematologic cancer	5.96e-05	0.000187	CcSEcCtD
Asenapine—Shock—Betamethasone—hematologic cancer	5.95e-05	0.000186	CcSEcCtD
Asenapine—Shock—Dexamethasone—hematologic cancer	5.95e-05	0.000186	CcSEcCtD
Asenapine—Dyspnoea—Triamcinolone—hematologic cancer	5.95e-05	0.000186	CcSEcCtD
Asenapine—Rash—Alitretinoin—hematologic cancer	5.94e-05	0.000186	CcSEcCtD
Asenapine—Nervous system disorder—Dexamethasone—hematologic cancer	5.93e-05	0.000186	CcSEcCtD
Asenapine—Nervous system disorder—Betamethasone—hematologic cancer	5.93e-05	0.000186	CcSEcCtD
Asenapine—Agitation—Prednisone—hematologic cancer	5.93e-05	0.000186	CcSEcCtD
Asenapine—Dermatitis—Alitretinoin—hematologic cancer	5.93e-05	0.000186	CcSEcCtD
Asenapine—Thrombocytopenia—Dexamethasone—hematologic cancer	5.93e-05	0.000186	CcSEcCtD
Asenapine—Thrombocytopenia—Betamethasone—hematologic cancer	5.93e-05	0.000186	CcSEcCtD
Asenapine—Vomiting—Ifosfamide—hematologic cancer	5.92e-05	0.000185	CcSEcCtD
Asenapine—Hypersensitivity—Cisplatin—hematologic cancer	5.91e-05	0.000185	CcSEcCtD
Asenapine—Tachycardia—Betamethasone—hematologic cancer	5.91e-05	0.000185	CcSEcCtD
Asenapine—Tachycardia—Dexamethasone—hematologic cancer	5.91e-05	0.000185	CcSEcCtD
Asenapine—Headache—Alitretinoin—hematologic cancer	5.9e-05	0.000185	CcSEcCtD
Asenapine—Angioedema—Prednisone—hematologic cancer	5.9e-05	0.000185	CcSEcCtD
Asenapine—Nausea—Thalidomide—hematologic cancer	5.88e-05	0.000184	CcSEcCtD
Asenapine—Dyspepsia—Triamcinolone—hematologic cancer	5.87e-05	0.000184	CcSEcCtD
Asenapine—Rash—Ifosfamide—hematologic cancer	5.87e-05	0.000184	CcSEcCtD
Asenapine—Dermatitis—Ifosfamide—hematologic cancer	5.86e-05	0.000184	CcSEcCtD
Asenapine—Dizziness—Irinotecan—hematologic cancer	5.85e-05	0.000183	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—hematologic cancer	5.83e-05	0.000183	CcSEcCtD
Asenapine—Malaise—Prednisone—hematologic cancer	5.82e-05	0.000182	CcSEcCtD
Asenapine—Eye disorder—Methotrexate—hematologic cancer	5.79e-05	0.000181	CcSEcCtD
Asenapine—Syncope—Prednisone—hematologic cancer	5.79e-05	0.000181	CcSEcCtD
Asenapine—Vomiting—Vincristine—hematologic cancer	5.77e-05	0.000181	CcSEcCtD
Asenapine—Asthenia—Cisplatin—hematologic cancer	5.76e-05	0.00018	CcSEcCtD
Asenapine—Cardiac disorder—Methotrexate—hematologic cancer	5.75e-05	0.00018	CcSEcCtD
Asenapine—Fatigue—Triamcinolone—hematologic cancer	5.75e-05	0.00018	CcSEcCtD
Asenapine—Rash—Vincristine—hematologic cancer	5.72e-05	0.000179	CcSEcCtD
Asenapine—Dermatitis—Vincristine—hematologic cancer	5.72e-05	0.000179	CcSEcCtD
Asenapine—Oedema peripheral—Epirubicin—hematologic cancer	5.72e-05	0.000179	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—hematologic cancer	5.7e-05	0.000179	CcSEcCtD
Asenapine—Headache—Vincristine—hematologic cancer	5.69e-05	0.000178	CcSEcCtD
Asenapine—Loss of consciousness—Prednisone—hematologic cancer	5.68e-05	0.000178	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—hematologic cancer	5.66e-05	0.000177	CcSEcCtD
Asenapine—Hypotension—Betamethasone—hematologic cancer	5.65e-05	0.000177	CcSEcCtD
Asenapine—Hypotension—Dexamethasone—hematologic cancer	5.65e-05	0.000177	CcSEcCtD
Asenapine—Nausea—Carmustine—hematologic cancer	5.65e-05	0.000177	CcSEcCtD
Asenapine—Angiopathy—Methotrexate—hematologic cancer	5.62e-05	0.000176	CcSEcCtD
Asenapine—Vomiting—Mitoxantrone—hematologic cancer	5.62e-05	0.000176	CcSEcCtD
Asenapine—Vomiting—Irinotecan—hematologic cancer	5.62e-05	0.000176	CcSEcCtD
Asenapine—Immune system disorder—Methotrexate—hematologic cancer	5.6e-05	0.000175	CcSEcCtD
Asenapine—Nausea—Alitretinoin—hematologic cancer	5.6e-05	0.000175	CcSEcCtD
Asenapine—Convulsion—Prednisone—hematologic cancer	5.6e-05	0.000175	CcSEcCtD
Asenapine—Mediastinal disorder—Methotrexate—hematologic cancer	5.59e-05	0.000175	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—hematologic cancer	5.58e-05	0.000175	CcSEcCtD
Asenapine—Hypertension—Prednisone—hematologic cancer	5.58e-05	0.000175	CcSEcCtD
Asenapine—Rash—Mitoxantrone—hematologic cancer	5.57e-05	0.000175	CcSEcCtD
Asenapine—Rash—Irinotecan—hematologic cancer	5.57e-05	0.000175	CcSEcCtD
Asenapine—Dermatitis—Irinotecan—hematologic cancer	5.57e-05	0.000174	CcSEcCtD
Asenapine—Dermatitis—Mitoxantrone—hematologic cancer	5.57e-05	0.000174	CcSEcCtD
Asenapine—Headache—Mitoxantrone—hematologic cancer	5.54e-05	0.000173	CcSEcCtD
Asenapine—Headache—Irinotecan—hematologic cancer	5.54e-05	0.000173	CcSEcCtD
Asenapine—Nausea—Ifosfamide—hematologic cancer	5.53e-05	0.000173	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	5.51e-05	0.000173	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	5.51e-05	0.000173	CcSEcCtD
Asenapine—Arthralgia—Prednisone—hematologic cancer	5.5e-05	0.000172	CcSEcCtD
Asenapine—Anxiety—Prednisone—hematologic cancer	5.48e-05	0.000172	CcSEcCtD
Asenapine—Vomiting—Gemcitabine—hematologic cancer	5.48e-05	0.000171	CcSEcCtD
Asenapine—Insomnia—Betamethasone—hematologic cancer	5.47e-05	0.000171	CcSEcCtD
Asenapine—Insomnia—Dexamethasone—hematologic cancer	5.47e-05	0.000171	CcSEcCtD
Asenapine—Mental disorder—Methotrexate—hematologic cancer	5.43e-05	0.00017	CcSEcCtD
Asenapine—Rash—Gemcitabine—hematologic cancer	5.43e-05	0.00017	CcSEcCtD
Asenapine—Dermatitis—Gemcitabine—hematologic cancer	5.42e-05	0.00017	CcSEcCtD
Asenapine—Eye disorder—Epirubicin—hematologic cancer	5.42e-05	0.00017	CcSEcCtD
Asenapine—Hypersensitivity—Etoposide—hematologic cancer	5.42e-05	0.00017	CcSEcCtD
Asenapine—Malnutrition—Methotrexate—hematologic cancer	5.4e-05	0.000169	CcSEcCtD
Asenapine—Headache—Gemcitabine—hematologic cancer	5.39e-05	0.000169	CcSEcCtD
Asenapine—Nausea—Vincristine—hematologic cancer	5.39e-05	0.000169	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—hematologic cancer	5.38e-05	0.000169	CcSEcCtD
Asenapine—Hypersensitivity—Prednisolone—hematologic cancer	5.34e-05	0.000167	CcSEcCtD
Asenapine—Dyspepsia—Dexamethasone—hematologic cancer	5.33e-05	0.000167	CcSEcCtD
Asenapine—Dyspepsia—Betamethasone—hematologic cancer	5.33e-05	0.000167	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—hematologic cancer	5.29e-05	0.000166	CcSEcCtD
Asenapine—Dysgeusia—Methotrexate—hematologic cancer	5.28e-05	0.000166	CcSEcCtD
Asenapine—Asthenia—Etoposide—hematologic cancer	5.28e-05	0.000165	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—hematologic cancer	5.28e-05	0.000165	CcSEcCtD
Asenapine—Anaphylactic shock—Prednisone—hematologic cancer	5.27e-05	0.000165	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—hematologic cancer	5.26e-05	0.000165	CcSEcCtD
Asenapine—Nausea—Mitoxantrone—hematologic cancer	5.25e-05	0.000164	CcSEcCtD
Asenapine—Nausea—Irinotecan—hematologic cancer	5.25e-05	0.000164	CcSEcCtD
Asenapine—Immune system disorder—Epirubicin—hematologic cancer	5.24e-05	0.000164	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—hematologic cancer	5.23e-05	0.000164	CcSEcCtD
Asenapine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.22e-05	0.000164	CcSEcCtD
Asenapine—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.22e-05	0.000164	CcSEcCtD
Asenapine—Fatigue—Dexamethasone—hematologic cancer	5.22e-05	0.000163	CcSEcCtD
Asenapine—Fatigue—Betamethasone—hematologic cancer	5.22e-05	0.000163	CcSEcCtD
Asenapine—Shock—Prednisone—hematologic cancer	5.19e-05	0.000162	CcSEcCtD
Asenapine—Nervous system disorder—Prednisone—hematologic cancer	5.17e-05	0.000162	CcSEcCtD
Asenapine—Tachycardia—Prednisone—hematologic cancer	5.14e-05	0.000161	CcSEcCtD
Asenapine—Nausea—Gemcitabine—hematologic cancer	5.12e-05	0.00016	CcSEcCtD
Asenapine—Vomiting—Cisplatin—hematologic cancer	5.1e-05	0.00016	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—hematologic cancer	5.08e-05	0.000159	CcSEcCtD
Asenapine—Rash—Cisplatin—hematologic cancer	5.06e-05	0.000159	CcSEcCtD
Asenapine—Dermatitis—Cisplatin—hematologic cancer	5.06e-05	0.000158	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—hematologic cancer	5.05e-05	0.000158	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—hematologic cancer	5.02e-05	0.000157	CcSEcCtD
Asenapine—Anaemia—Methotrexate—hematologic cancer	4.99e-05	0.000156	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—hematologic cancer	4.98e-05	0.000156	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—hematologic cancer	4.95e-05	0.000155	CcSEcCtD
Asenapine—Hypersensitivity—Triamcinolone—hematologic cancer	4.91e-05	0.000154	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—hematologic cancer	4.87e-05	0.000153	CcSEcCtD
Asenapine—Malaise—Methotrexate—hematologic cancer	4.87e-05	0.000152	CcSEcCtD
Asenapine—Dizziness—Etoposide—hematologic cancer	4.86e-05	0.000152	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—hematologic cancer	4.86e-05	0.000152	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—hematologic cancer	4.85e-05	0.000152	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—hematologic cancer	4.84e-05	0.000152	CcSEcCtD
Asenapine—Leukopenia—Methotrexate—hematologic cancer	4.83e-05	0.000151	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.8e-05	0.00015	CcSEcCtD
Asenapine—Dizziness—Prednisolone—hematologic cancer	4.8e-05	0.00015	CcSEcCtD
Asenapine—Asthenia—Triamcinolone—hematologic cancer	4.79e-05	0.00015	CcSEcCtD
Asenapine—Nausea—Cisplatin—hematologic cancer	4.77e-05	0.000149	CcSEcCtD
Asenapine—Insomnia—Prednisone—hematologic cancer	4.77e-05	0.000149	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—hematologic cancer	4.7e-05	0.000147	CcSEcCtD
Asenapine—Convulsion—Methotrexate—hematologic cancer	4.68e-05	0.000146	CcSEcCtD
Asenapine—Vomiting—Etoposide—hematologic cancer	4.68e-05	0.000146	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—hematologic cancer	4.67e-05	0.000146	CcSEcCtD
Asenapine—Anaemia—Epirubicin—hematologic cancer	4.67e-05	0.000146	CcSEcCtD
Asenapine—Agitation—Epirubicin—hematologic cancer	4.64e-05	0.000145	CcSEcCtD
Asenapine—Dyspepsia—Prednisone—hematologic cancer	4.64e-05	0.000145	CcSEcCtD
Asenapine—Rash—Etoposide—hematologic cancer	4.64e-05	0.000145	CcSEcCtD
Asenapine—Dermatitis—Etoposide—hematologic cancer	4.63e-05	0.000145	CcSEcCtD
Asenapine—Headache—Etoposide—hematologic cancer	4.61e-05	0.000144	CcSEcCtD
Asenapine—Arthralgia—Methotrexate—hematologic cancer	4.59e-05	0.000144	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—hematologic cancer	4.58e-05	0.000143	CcSEcCtD
Asenapine—Rash—Prednisolone—hematologic cancer	4.57e-05	0.000143	CcSEcCtD
Asenapine—Dermatitis—Prednisolone—hematologic cancer	4.57e-05	0.000143	CcSEcCtD
Asenapine—Malaise—Epirubicin—hematologic cancer	4.55e-05	0.000143	CcSEcCtD
Asenapine—Fatigue—Prednisone—hematologic cancer	4.54e-05	0.000142	CcSEcCtD
Asenapine—Headache—Prednisolone—hematologic cancer	4.54e-05	0.000142	CcSEcCtD
Asenapine—Syncope—Epirubicin—hematologic cancer	4.53e-05	0.000142	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—hematologic cancer	4.52e-05	0.000142	CcSEcCtD
Asenapine—Constipation—Prednisone—hematologic cancer	4.51e-05	0.000141	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—hematologic cancer	4.49e-05	0.000141	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—hematologic cancer	4.44e-05	0.000139	CcSEcCtD
Asenapine—Dizziness—Triamcinolone—hematologic cancer	4.41e-05	0.000138	CcSEcCtD
Asenapine—Anaphylactic shock—Methotrexate—hematologic cancer	4.4e-05	0.000138	CcSEcCtD
Asenapine—Convulsion—Epirubicin—hematologic cancer	4.38e-05	0.000137	CcSEcCtD
Asenapine—Nausea—Etoposide—hematologic cancer	4.37e-05	0.000137	CcSEcCtD
Asenapine—Hypertension—Epirubicin—hematologic cancer	4.36e-05	0.000137	CcSEcCtD
Asenapine—Asthenia—Betamethasone—hematologic cancer	4.34e-05	0.000136	CcSEcCtD
Asenapine—Asthenia—Dexamethasone—hematologic cancer	4.34e-05	0.000136	CcSEcCtD
Asenapine—Nervous system disorder—Methotrexate—hematologic cancer	4.32e-05	0.000135	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—hematologic cancer	4.32e-05	0.000135	CcSEcCtD
Asenapine—Thrombocytopenia—Methotrexate—hematologic cancer	4.31e-05	0.000135	CcSEcCtD
Asenapine—Nausea—Prednisolone—hematologic cancer	4.31e-05	0.000135	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—hematologic cancer	4.3e-05	0.000135	CcSEcCtD
Asenapine—Agitation—Doxorubicin—hematologic cancer	4.29e-05	0.000135	CcSEcCtD
Asenapine—Anxiety—Epirubicin—hematologic cancer	4.28e-05	0.000134	CcSEcCtD
Asenapine—Vomiting—Triamcinolone—hematologic cancer	4.24e-05	0.000133	CcSEcCtD
Asenapine—Malaise—Doxorubicin—hematologic cancer	4.21e-05	0.000132	CcSEcCtD
Asenapine—Rash—Triamcinolone—hematologic cancer	4.21e-05	0.000132	CcSEcCtD
Asenapine—Dry mouth—Epirubicin—hematologic cancer	4.21e-05	0.000132	CcSEcCtD
Asenapine—Dermatitis—Triamcinolone—hematologic cancer	4.2e-05	0.000132	CcSEcCtD
Asenapine—Syncope—Doxorubicin—hematologic cancer	4.19e-05	0.000131	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—hematologic cancer	4.18e-05	0.000131	CcSEcCtD
Asenapine—Headache—Triamcinolone—hematologic cancer	4.18e-05	0.000131	CcSEcCtD
Asenapine—Anaphylactic shock—Epirubicin—hematologic cancer	4.12e-05	0.000129	CcSEcCtD
Asenapine—Hypotension—Methotrexate—hematologic cancer	4.12e-05	0.000129	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—hematologic cancer	4.11e-05	0.000129	CcSEcCtD
Asenapine—Shock—Epirubicin—hematologic cancer	4.06e-05	0.000127	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—hematologic cancer	4.05e-05	0.000127	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—hematologic cancer	4.04e-05	0.000127	CcSEcCtD
Asenapine—Thrombocytopenia—Epirubicin—hematologic cancer	4.04e-05	0.000126	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—hematologic cancer	4.03e-05	0.000126	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—hematologic cancer	4.02e-05	0.000126	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.01e-05	0.000126	CcSEcCtD
Asenapine—Dizziness—Dexamethasone—hematologic cancer	4e-05	0.000125	CcSEcCtD
Asenapine—Dizziness—Betamethasone—hematologic cancer	4e-05	0.000125	CcSEcCtD
Asenapine—Insomnia—Methotrexate—hematologic cancer	3.98e-05	0.000125	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—hematologic cancer	3.98e-05	0.000125	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—hematologic cancer	3.96e-05	0.000124	CcSEcCtD
Asenapine—Nausea—Triamcinolone—hematologic cancer	3.96e-05	0.000124	CcSEcCtD
Asenapine—Dyspnoea—Methotrexate—hematologic cancer	3.93e-05	0.000123	CcSEcCtD
Asenapine—Somnolence—Methotrexate—hematologic cancer	3.92e-05	0.000123	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—hematologic cancer	3.89e-05	0.000122	CcSEcCtD
Asenapine—Hypersensitivity—Prednisone—hematologic cancer	3.88e-05	0.000122	CcSEcCtD
Asenapine—Dyspepsia—Methotrexate—hematologic cancer	3.88e-05	0.000121	CcSEcCtD
Asenapine—Hypotension—Epirubicin—hematologic cancer	3.85e-05	0.000121	CcSEcCtD
Asenapine—Vomiting—Dexamethasone—hematologic cancer	3.85e-05	0.000121	CcSEcCtD
Asenapine—Vomiting—Betamethasone—hematologic cancer	3.85e-05	0.000121	CcSEcCtD
Asenapine—Rash—Betamethasone—hematologic cancer	3.82e-05	0.00012	CcSEcCtD
Asenapine—Rash—Dexamethasone—hematologic cancer	3.82e-05	0.00012	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—hematologic cancer	3.81e-05	0.000119	CcSEcCtD
Asenapine—Dermatitis—Dexamethasone—hematologic cancer	3.81e-05	0.000119	CcSEcCtD
Asenapine—Dermatitis—Betamethasone—hematologic cancer	3.81e-05	0.000119	CcSEcCtD
Asenapine—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.8e-05	0.000119	CcSEcCtD
Asenapine—Fatigue—Methotrexate—hematologic cancer	3.8e-05	0.000119	CcSEcCtD
Asenapine—Headache—Betamethasone—hematologic cancer	3.79e-05	0.000119	CcSEcCtD
Asenapine—Headache—Dexamethasone—hematologic cancer	3.79e-05	0.000119	CcSEcCtD
Asenapine—Asthenia—Prednisone—hematologic cancer	3.78e-05	0.000118	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.76e-05	0.000118	CcSEcCtD
Asenapine—Shock—Doxorubicin—hematologic cancer	3.75e-05	0.000118	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—hematologic cancer	3.74e-05	0.000117	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—hematologic cancer	3.73e-05	0.000117	CcSEcCtD
Asenapine—Insomnia—Epirubicin—hematologic cancer	3.73e-05	0.000117	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—hematologic cancer	3.72e-05	0.000117	CcSEcCtD
Asenapine—Dyspnoea—Epirubicin—hematologic cancer	3.67e-05	0.000115	CcSEcCtD
Asenapine—Somnolence—Epirubicin—hematologic cancer	3.66e-05	0.000115	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—hematologic cancer	3.63e-05	0.000114	CcSEcCtD
Asenapine—Nausea—Dexamethasone—hematologic cancer	3.59e-05	0.000113	CcSEcCtD
Asenapine—Nausea—Betamethasone—hematologic cancer	3.59e-05	0.000113	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—hematologic cancer	3.56e-05	0.000112	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.56e-05	0.000111	CcSEcCtD
Asenapine—Fatigue—Epirubicin—hematologic cancer	3.55e-05	0.000111	CcSEcCtD
Asenapine—Constipation—Epirubicin—hematologic cancer	3.52e-05	0.00011	CcSEcCtD
Asenapine—Dizziness—Prednisone—hematologic cancer	3.49e-05	0.000109	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.47e-05	0.000109	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—hematologic cancer	3.45e-05	0.000108	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—hematologic cancer	3.4e-05	0.000106	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—hematologic cancer	3.39e-05	0.000106	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—hematologic cancer	3.36e-05	0.000105	CcSEcCtD
Asenapine—Vomiting—Prednisone—hematologic cancer	3.35e-05	0.000105	CcSEcCtD
Asenapine—Rash—Prednisone—hematologic cancer	3.32e-05	0.000104	CcSEcCtD
Asenapine—Dermatitis—Prednisone—hematologic cancer	3.32e-05	0.000104	CcSEcCtD
Asenapine—Headache—Prednisone—hematologic cancer	3.3e-05	0.000103	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Asenapine—Constipation—Doxorubicin—hematologic cancer	3.26e-05	0.000102	CcSEcCtD
Asenapine—Hypersensitivity—Methotrexate—hematologic cancer	3.25e-05	0.000102	CcSEcCtD
Asenapine—Asthenia—Methotrexate—hematologic cancer	3.16e-05	9.9e-05	CcSEcCtD
Asenapine—Nausea—Prednisone—hematologic cancer	3.13e-05	9.8e-05	CcSEcCtD
Asenapine—Hypersensitivity—Epirubicin—hematologic cancer	3.04e-05	9.51e-05	CcSEcCtD
Asenapine—Asthenia—Epirubicin—hematologic cancer	2.96e-05	9.26e-05	CcSEcCtD
Asenapine—Dizziness—Methotrexate—hematologic cancer	2.91e-05	9.12e-05	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—hematologic cancer	2.81e-05	8.8e-05	CcSEcCtD
Asenapine—Vomiting—Methotrexate—hematologic cancer	2.8e-05	8.77e-05	CcSEcCtD
Asenapine—Rash—Methotrexate—hematologic cancer	2.78e-05	8.7e-05	CcSEcCtD
Asenapine—Dermatitis—Methotrexate—hematologic cancer	2.77e-05	8.69e-05	CcSEcCtD
Asenapine—Headache—Methotrexate—hematologic cancer	2.76e-05	8.64e-05	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—hematologic cancer	2.74e-05	8.57e-05	CcSEcCtD
Asenapine—Dizziness—Epirubicin—hematologic cancer	2.73e-05	8.54e-05	CcSEcCtD
Asenapine—Vomiting—Epirubicin—hematologic cancer	2.62e-05	8.21e-05	CcSEcCtD
Asenapine—Nausea—Methotrexate—hematologic cancer	2.62e-05	8.19e-05	CcSEcCtD
Asenapine—Rash—Epirubicin—hematologic cancer	2.6e-05	8.14e-05	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—hematologic cancer	2.6e-05	8.13e-05	CcSEcCtD
Asenapine—Headache—Epirubicin—hematologic cancer	2.58e-05	8.09e-05	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—hematologic cancer	2.52e-05	7.9e-05	CcSEcCtD
Asenapine—Nausea—Epirubicin—hematologic cancer	2.45e-05	7.67e-05	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—hematologic cancer	2.42e-05	7.6e-05	CcSEcCtD
Asenapine—Rash—Doxorubicin—hematologic cancer	2.4e-05	7.53e-05	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—hematologic cancer	2.4e-05	7.52e-05	CcSEcCtD
Asenapine—Headache—Doxorubicin—hematologic cancer	2.39e-05	7.48e-05	CcSEcCtD
Asenapine—Nausea—Doxorubicin—hematologic cancer	2.27e-05	7.1e-05	CcSEcCtD
Asenapine—DRD2—Signaling Pathways—CCND1—hematologic cancer	2.12e-06	1.23e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	2.12e-06	1.23e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	2.12e-06	1.23e-05	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	2.12e-06	1.23e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—JUN—hematologic cancer	2.12e-06	1.23e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.11e-06	1.23e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	2.1e-06	1.22e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	2.1e-06	1.22e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.1e-06	1.22e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—SRC—hematologic cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—EP300—hematologic cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—hematologic cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.09e-06	1.21e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	2.09e-06	1.21e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.09e-06	1.21e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—hematologic cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—hematologic cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—JUN—hematologic cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.07e-06	1.2e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.07e-06	1.2e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	2.07e-06	1.2e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—hematologic cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—hematologic cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—hematologic cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—hematologic cancer	2.05e-06	1.2e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—hematologic cancer	2.05e-06	1.19e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—hematologic cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—hematologic cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	2.02e-06	1.18e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.02e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	2.02e-06	1.17e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	2.02e-06	1.17e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.02e-06	1.17e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—hematologic cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK8—hematologic cancer	2e-06	1.17e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	2e-06	1.17e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—CREBBP—hematologic cancer	2e-06	1.16e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—hematologic cancer	2e-06	1.16e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—hematologic cancer	2e-06	1.16e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	1.99e-06	1.16e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.99e-06	1.16e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	1.98e-06	1.15e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—hematologic cancer	1.98e-06	1.15e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	1.98e-06	1.15e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	1.98e-06	1.15e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—IL6—hematologic cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK8—hematologic cancer	1.97e-06	1.14e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—hematologic cancer	1.97e-06	1.14e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—IL6—hematologic cancer	1.97e-06	1.14e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	1.97e-06	1.14e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—hematologic cancer	1.96e-06	1.14e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—hematologic cancer	1.96e-06	1.14e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.96e-06	1.14e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—IL6—hematologic cancer	1.95e-06	1.14e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EP300—hematologic cancer	1.95e-06	1.14e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.95e-06	1.14e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.95e-06	1.13e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.94e-06	1.13e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.94e-06	1.13e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.93e-06	1.13e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.93e-06	1.12e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	1.93e-06	1.12e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—hematologic cancer	1.93e-06	1.12e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.93e-06	1.12e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EP300—hematologic cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	1.91e-06	1.11e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—IL6—hematologic cancer	1.91e-06	1.11e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—SRC—hematologic cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.9e-06	1.1e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.9e-06	1.1e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	1.89e-06	1.1e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—IL6—hematologic cancer	1.88e-06	1.1e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.88e-06	1.09e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—hematologic cancer	1.88e-06	1.09e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	1.88e-06	1.09e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—hematologic cancer	1.87e-06	1.09e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—ALB—hematologic cancer	1.87e-06	1.09e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	1.87e-06	1.09e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.87e-06	1.09e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—SRC—hematologic cancer	1.87e-06	1.08e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.86e-06	1.08e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—hematologic cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.84e-06	1.07e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—hematologic cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.83e-06	1.06e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.83e-06	1.06e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.83e-06	1.06e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—hematologic cancer	1.83e-06	1.06e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.82e-06	1.06e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—hematologic cancer	1.82e-06	1.06e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—hematologic cancer	1.82e-06	1.06e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—hematologic cancer	1.81e-06	1.06e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.8e-06	1.05e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—hematologic cancer	1.8e-06	1.05e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—STAT3—hematologic cancer	1.8e-06	1.05e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.8e-06	1.05e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—IL6—hematologic cancer	1.8e-06	1.05e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—hematologic cancer	1.79e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.79e-06	1.04e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.79e-06	1.04e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.79e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.79e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.78e-06	1.04e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	1.78e-06	1.04e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—hematologic cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—hematologic cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.76e-06	1.02e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.75e-06	1.02e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.75e-06	1.02e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—hematologic cancer	1.75e-06	1.02e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—hematologic cancer	1.74e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.72e-06	1e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	1.72e-06	1e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK3—hematologic cancer	1.72e-06	1e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.71e-06	9.92e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—hematologic cancer	1.7e-06	9.9e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.7e-06	9.89e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.7e-06	9.88e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.7e-06	9.86e-06	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—IL6—hematologic cancer	1.69e-06	9.86e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.69e-06	9.81e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	1.68e-06	9.79e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.68e-06	9.77e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.68e-06	9.74e-06	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—IL6—hematologic cancer	1.67e-06	9.73e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—hematologic cancer	1.67e-06	9.72e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.67e-06	9.72e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TGFB1—hematologic cancer	1.67e-06	9.7e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—hematologic cancer	1.66e-06	9.68e-06	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—hematologic cancer	1.66e-06	9.64e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.66e-06	9.63e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.65e-06	9.62e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.65e-06	9.59e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.65e-06	9.57e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.64e-06	9.54e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.64e-06	9.54e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.64e-06	9.52e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.64e-06	9.52e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.64e-06	9.52e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—hematologic cancer	1.63e-06	9.47e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.61e-06	9.35e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	1.59e-06	9.26e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.59e-06	9.26e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—hematologic cancer	1.59e-06	9.26e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ALB—hematologic cancer	1.59e-06	9.23e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.58e-06	9.21e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	1.58e-06	9.18e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.57e-06	9.15e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.57e-06	9.11e-06	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—hematologic cancer	1.56e-06	9.1e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—hematologic cancer	1.56e-06	9.06e-06	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—hematologic cancer	1.56e-06	9.05e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.55e-06	9e-06	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.55e-06	9e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—hematologic cancer	1.54e-06	8.98e-06	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—hematologic cancer	1.54e-06	8.97e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	1.54e-06	8.96e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.52e-06	8.86e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL6—hematologic cancer	1.52e-06	8.86e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.52e-06	8.86e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.52e-06	8.84e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.52e-06	8.83e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.52e-06	8.82e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.51e-06	8.81e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.51e-06	8.78e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL6—hematologic cancer	1.49e-06	8.67e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.47e-06	8.57e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.46e-06	8.48e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.45e-06	8.43e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.45e-06	8.41e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.43e-06	8.31e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.42e-06	8.27e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	1.42e-06	8.25e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.41e-06	8.21e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	1.41e-06	8.2e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.41e-06	8.19e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—hematologic cancer	1.41e-06	8.18e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.4e-06	8.15e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—hematologic cancer	1.4e-06	8.13e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.39e-06	8.1e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.39e-06	8.1e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.38e-06	8e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—hematologic cancer	1.38e-06	8e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—hematologic cancer	1.37e-06	7.98e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—EP300—hematologic cancer	1.36e-06	7.93e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.35e-06	7.83e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.34e-06	7.82e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.34e-06	7.78e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.34e-06	7.78e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.32e-06	7.65e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—hematologic cancer	1.31e-06	7.64e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.31e-06	7.61e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.3e-06	7.57e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.29e-06	7.52e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.29e-06	7.49e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL6—hematologic cancer	1.28e-06	7.44e-06	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—hematologic cancer	1.26e-06	7.35e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.26e-06	7.32e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL6—hematologic cancer	1.26e-06	7.31e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.25e-06	7.28e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.24e-06	7.22e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.23e-06	7.17e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ALB—hematologic cancer	1.22e-06	7.12e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—hematologic cancer	1.21e-06	7.04e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.2e-06	6.96e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.18e-06	6.87e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.17e-06	6.81e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.16e-06	6.76e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.16e-06	6.74e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—EP300—hematologic cancer	1.15e-06	6.72e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.15e-06	6.66e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.14e-06	6.62e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.08e-06	6.29e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.06e-06	6.15e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.01e-06	5.86e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—hematologic cancer	9.34e-07	5.43e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—EP300—hematologic cancer	8.91e-07	5.18e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	8.54e-07	4.97e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—hematologic cancer	8.24e-07	4.79e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—hematologic cancer	6.98e-07	4.06e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.59e-07	3.83e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—hematologic cancer	5.38e-07	3.13e-06	CbGpPWpGaD
